THERAPEUTIC INDICATIONS
- Curative treatment of torsades de pointe (TdP)
- Treatment of acute hypokalemia associated with hypomagnesemia
- Magnesium supplement during electrolyte rebalance
- Magnesium supplement in parenteral nutrition
- Preventive and curative treatment of eclampsia crisis
PHARMACEUTICAL FORM
The magnesium sulfate 15% solution is packaged in a polypropylene ampoule manufactured according to the BFS (blow fill seal) process. Its tip allows the direct connection of a syringe thanks to the luer lock system.
The bfs ampoules are available in strips of 5 units which can be individually detached from each other easily.
PHARMACO-THERAPEUTIC CLASS
Magnesium salts solution (B 05 CB) (B: Hematopoietic stem cells blood and lymphoid organs)
PHARMACODYNAMICS
Physiologically :
Magnesium is a cation primarily intracellular. It decreases neuronal excitability and neuromuscular transmission and is involved in several enzymatic reactions. Constitutional element, half of magnesium builds bone mass.
Clinically :
Serum magnesemia :
- ranging from 12 to 17 mg/l (1 to 1.4 mEq/l or 0.5 to 0.7 mmol/l) indicates moderate magnesium deficiency,
- under 12 mg/l (1 mEq/l or 0.5 mmol/l) indicates severe magnesium deficiency.
Magnesium deficiency may be :
- Primary by congenital abnormality of metabolism (chronic congenital hypomagnesemia).
- Secondary by :
- inadequate nutritional supplements (severe denutrition, alcoholism, parenteral nutrition exclusively),
- digestive malabsorption (chronic diarrhoea, digestive fistulas, hypoparathyroidy),
- excessive increase of renal losses (tubulopathies, severe polyurias, diuretics abuse, chronic pyelonephritis, primary hyperaldosteronism, treatment with cisplatin).
PHARMACOKINETICS
Urinay excretion mainly.
